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a  b  s  t  r  a  c  t
Background: It is believed that Human Papillomavirus (HPV) and Human Immunodeﬁciency
Virus  coinfection contributes to increase the risk for cervical intraepithelial injuries. Several
factors  may contribute to cervical cancer (CC) development, including genetic variants such
as  TP53 and MDM2 gene polymorphisms.
Materials  and methods: A hundred HIV-infected women were examined for HPV detection
and  its genotypes, as well as the frequencies of the SNPs Arg72Pro and SNP309 and their
associations  with CC risk factors. Nested Polymerase Chain Reaction (nPCR) was  used for
HPV  detection and PCR-RFLP for TP53 and MDM2 SNP309 genotyping.
Results:  HPV DNA was detected in 68% of samples. A higher frequency of low-risk HPV geno-
types  (66.7%) was observed when compared to high-risk genotypes (33.3%). Nine different
HPV  genotypes were identiﬁed, with the highest prevalence of HPV-6, followed by HPV-16
and  31. p53 Arg72Arg and SNP309 TG genotype were the most prevalent. HPV genotyping
was  performed by sequencing.
Conclusion:  The data obtained suggest that HIV-infected women are more susceptible to
be  infected by low-risk HPV (LR-HPV) genotypes than by high-risk (HR-HPV), and Pro72Pro
of  TP53 gene and TG of MDM2 SNP309 genotypes apparently seem to be protective fac-
tors  among HIV-infected women for HPV acquisition and HR-HPV infection, respectively,
in  a sample of Southern Brazilian woman. Future investigations in larger populations arendernecessary  to better uoncogenic  HPV genotypes
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Introduction
It is estimated that cervical cancer (CC) is the second most
common  type of cancer in the Brazilian female population
and  the third cause of death in women.1 Today, it is possi-
ble  to conﬁrm that CC development is closely associated with
the  Human Papillomavirus (HPV) presence and persistence,2
with HPV DNA detected in up to 99.7% of invasive CC cases
across  the world.3 The World Health Organization attributes
to  cervical infection with HPV-16 or -18 about 70% of inva-
sive  CC cases in Brazil.4 Cervical intraepithelial neoplasia (CIN)
development  and cervical cancer in HPV-infected women are
associated with risk factors, such as young age, high number of
sexual  partners throughout life, early sexual debut, smoking,
genetics  variants, among others.5,6 Moreover, co-infections,
such as those with Human Immunodeﬁciency Virus (HIV) and
Chlamydia  trachomatis bacterium, may  be involved as co-factors
to  CC development, acting as adjuvants of the neoplastic
process.7,8
The polymorphism on codon 72 (Arg72Pro) of TP53
tumor suppressor gene has been extensively investigated
regarding association with a wide range of cancers world-
wide.  In HPV-infected cells, the E6 oncoprotein binds to
p53  protein and promotes its degradation through an
ubiquitin proteolytic system altering the p53 activity in
some  processes, such as tumorigenesis, transcription regu-
lation,  telomerase activation, and apoptosis, thus resulting
in  deregulation of the cell cycle.9 Previous studies have
shown that the Arg72Arg genotype is related to a higher
risk  for CC development when compared to the Pro72Pro
genotype.10
Studies have shown that a Single Nucleotide Polymorphism
(SNP) on promoter region of MDM2  gene, the SNP309 (T to
G  change on nucleotide 309 of the ﬁrst intron), results in a
higher  level of MDM2 mRNA  and MDM2  protein, and conse-
quent  reduction of the p53 pathway.11 The SNP309 occurs at
a  relatively high frequency in the general population, and it
was shown that it presents a strong association with HPV-
mediated  cervical carcinogenesis.12
Based on the presented data, this study aimed to inves-
tigate the HPV infection spectrum, to identify the most
prevalent genotypes, to determine the frequencies of SNPs
Arg72Pro  and MDM2  SNP309, and their association with
possible  risk factors for viral persistence and for the devel-
opment  of pre-neoplastic and neoplastic lesions of the
uterine  cervix in HIV-infected women. The study was  con-
ducted  in patients of the Service of Specialized Care for
HIV/AIDS, College of Medicine, Federal University of Pelotas
(Servic¸o  de Assistência Especializada em HIV/SIDA – SAE-
UFPel).
Materials  and  methods
Study  type,  characterization  and  sample  sizeThis was  a cross-sectional study consisting of 100 HIV-infected
women, which were  sequentially randomly invited to partic-
ipate.  The eligibility criteria were: not being in the menstrual 1 4;1  8(6):643–650
period,  aged between 18 and 45 years, and not being pregnant.
Women  who had undergone cervical conization and/or hys-
terectomy  were excluded. The Epi-Info 6.0 software was  used
to  calculate the required sample size for the prevalence study,
using  an estimated HPV prevalence of 80%, with a 95% conﬁ-
dence  level and 80% testing power.
Logistics
All participants completed a standardized questionnaire with
the  purpose of obtaining information about the patient
and  other relevant epidemiological and socio-demographic
variables. An adapted questionnaire from an intervention
study with HIV-infected (HIV+) women conducted at SAE-
UFPel  was used.13 The Research Ethics Committee of the
College  of Medicine of the Federal University of Pelotas
approved the present study by June 2009, and informed
consent was obtained from all participants. All procedures
were  conducted according to the Helsinki Declaration guide-
lines.
Sample  collection  and  DNA  extraction
Cytobrushes were collected containing cervical secretion sam-
ples  from the endocervical region. The collected samples
were  stored in eppendorf tubes containing 300 L of Cellular
Lysis  Solution (PUREGENETMGentra Systems Kit) and routed
in  an appropriated container to the Laboratory of Functional
Genomics (Center for Technology Development – CDTec-
UFPel)  for viral molecular detection by Polymerase Chain
Reaction (PCR). Before DNA extraction, the samples were  sub-
jected  to enzymatic digestion with 1.5 L of Proteinase K
(10  mg/mL) and incubated for 16 h at room temperature. The
extracted  DNA was  performed according to manufacturer’s
speciﬁcations (PUREGENETMGentra Systems Kit).
TP53  gene  polymorphism  analysis
The Arg72Pro polymorphism of TP53 gene was  analyzed by
PCR  using the 72A and 72S primers described by Lin et al.14 The
ampliﬁcation conditions consisted of an initial denaturation
at  94 ◦C for 3 min  followed by 40 cycles at 94 ◦C for 30 s, 57 ◦C
for  30 s, 72 ◦C for 30 s, and a ﬁnal extension at 72 ◦C for 3 min.
The PCR product obtained was  subjected to enzymatic
digestion by RFLP (Restriction Fragment Length Polymor-
phism) using the Bst UI restriction enzyme for restriction
fragments analysis. The fragments obtained were  analyzed
by  agarose gel electrophoresis (2.5% agarose in TBE buffer),
stained  with GelRedTM (Biotium Inc., CA) and observed under
ultraviolet light (UV). The p53 genotypes were characterized
according to Lin et al.14
MDM2  SNP309  analysis
The MDM2 T/G SNP309 polymorphism was  analyzed by PCR
using  the primers described by Sotomaa et al.15 The reaction
◦was  performed with initial denaturing at 94 C for 10 min  fol-
lowed  by 30 subsequent cycles at 94 ◦C for 30 s, 60 ◦C for 1 min,
72 ◦C for 1 min, and a ﬁnal extension at 72 ◦C for 10 min. The
PCR  products were  analyzed by agarose gel electrophoresis (2%
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garose gel in TBE buffer), stained with GelRedTM (Biotium Inc.,
A)  and observed under UV. The genotyping was performed by
FLP using the MspA1 l restriction enzyme.15
PV  DNA  detection  by  PCR
he HPV DNA detection was  performed by the nested PCR
nPCR)  technique, which is performed in two stages. The
rst  stage used a pair of external primers (MY09/11) pre-
iously  described by Manos et al.,16 and the second stage
sed  a pair of internal primers (GP5/6) described by Snijders
t  al.17 Both reactions were  performed with initial denatur-
ng  at 95 ◦C during 9 min  and ﬁnal extension at 72 ◦C for
 min.18,19 The reaction conditions for the ﬁrst stage consisted
f  40 subsequent cycles of 94 ◦C during 30 s for denaturation,
5 ◦C during 30 s for annealing, and 72 ◦C for 30 s for exten-
ion.  For the second stage were  used 40 subsequent cycles of
5 ◦C for 1 min, 55 ◦C for 1 min, and 72 ◦C for 1 min  for dena-
uration, annealing and extension, respectively.19 The PCR
roducts  obtained were subjected to agarose gel electrophore-
is  (1.0% and 2.0% agarose for the ﬁrst and second rounds,
espectively) and observed under UV. A reaction positive con-
rol  (RPC) consisting of 450pb corresponding to HeLa cells
HPV-16)  and a negative control (NC) without any DNA were
sed.
equencing  of  the  PCR  products
he HPV DNA-positive samples were  sequenced for identiﬁ-
ation  of the present genotypes. The products obtained from
PCR  were  puriﬁed using the IllustraTM GFXTM PCR DNA and
el  Band Puriﬁcation Kit (GE Health Care) and sequenced on a
egaBACE 500 (GE Healthcare).
equence  analyses
orward and reverse sequences were aligned and a consen-
us  sequence was  obtained for each case using VECTOR NTI®
0.0 software. The genotypes were  determined comparing the
onsensus  sequence with reference sequences deposited in
NA databases through the nucleotide Basic Local Search Tool
BLASTn). For the samples edition and alignment, the VECTOR
TI® 10.0 software was  used.
ata  analyze
ata was  entered by two different data clerks with the
oftware Epi-Info® Windows version in order to make a fur-
her  comparison and, thus, ensure better data quality. An
utomatic  data checking was  performed at the time of typ-
ng  using the Epi-Info® Check function for consistency and
mplitude checking. To identify and correct coding, proof-
eading  and typing inconsistencies, a data cleaning was
erformed by obtaining frequencies of the collected vari-
bles.  The analysis was  performed using the SPSS® v16.0
2oftware. Chi-square tests ( ) were  used for the univariate
nalyses. Multivariate logistic regression analysis was also
erformed.  Variables remained at the model if their level of
igniﬁcance  was  below 0.20, as potential confounders for the4;1 8(6):643–650  645
next level. A p-value < 0.05 was  considered statistically signif-
icant.
Results
Most participants were aged between 40 and 45 years (53%),
were  white (51%), 45.3% had between ﬁve and eight years of
education,  were  married or in a stable relationship (64.4%),
and  the overriding majority had per capita income of one mini-
mum  wage (96.6%). Regarding behavioral variables, 59.6% were
non-smokers, 60% reported not having consumed alcohol in
the last four weeks, 63.3% reported having used a condom at
last  sexual intercourse, 56% were aged between 12 and 15 years
at  sexual debut, 40.8% had more  than nine sexual partners
throughout life, and over 90% reported never had exchanged
sex  for money and/or drugs.
The  TP53 genotyping showed that, out of the 100 sam-
ples  analyzed, 43% presented Arg72Pro genotype, 39% were
Arg72Arg  and 18% were  Pro72Pro. The alleles frequency
showed 82% for the A (AA + AP) allele and 61% for the P (AP + PP)
allele.  The MDM2 SNP309 genotyping showed a higher fre-
quency  for the TG genotype (45%). Moreover, the T (TT + TG)
allele  was  the most frequent (84%) compared to the G (GG + TG)
allele (61%).
HPV  infection was observed in 68% of the samples. Nine dif-
ferent  HPV genotypes were found, with a higher prevalence
of  HPV-6, followed by HPV-16, HPV-31, HPV-11, HPV-18, HPV-
35,  HPV-45, HPV-56 and HPV-81. Eleven samples could not be
genotyped by sequencing, and these were categorized as HPV-
X.  According to the epidemiologic classiﬁcation of HPV types
associated  with cervical cancer, 33.3% of the samples were
high-risk  oncogenic HPV (HR-HPV) and 66.7% were  low-risk
oncogenic HPV (LR-HPV).20
Table 1 shows the univariate analysis, having HPV infec-
tion  as outcome related to socioeconomic, demographic and
behavioral  variables. There was  no statistically signiﬁcant
association with any of the variables. Table 2 shows the fre-
quency  distribution of genotypes and alleles of Arg72Pro and
MDM2  SNP309. The Arg72Arg genotype of the TP53 gene was
the  most prevalent among the HPV+ group (45.6%), predomi-
nating  A (AA + AP) allele (82.4%) compared to P (AP + PP) allele
(54.4%).  The MDM2 SNP309 presented the TG genotype as
the  most prevalent (50%), as well as the T (TT + TG) allele
(83.8%) when compared to the G (GG + TG) allele (66.2%). The
LR-HPV  infected group showed frequencies similar to those
shown  by the HR-HPV infected group, except for some vari-
ables.  Regarding the TP53 gene polymorphism, it was observed
that  52.6% of the HR-HPV infected samples and 47.4% of the
LR-HPV  infected samples presented the Arg72Arg genotype.
In  addition, the A (AA + AP) allele was more  frequent in both
infections  (LR and HR) when compared to the P (AP + PP) allele
(p  < 0.05). Furthermore, the MDM2 SNP309 genotyping showed
a  higher frequency of TT genotype (42.1%) in the HR-HPV
group, as well as higher frequency of TG genotype (65.8%) in
the  LR-HPV group (p < 0.05). The T (TT + TG) allele was  more
frequent  when compared to the G (GG + TG) allele in both
groups.
The  multivariate analyses showed no statistically signiﬁ-
cant  differences and their results are not reported here.
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Table 1 – Interaction of HPV infection and the oncogenic potential risk on the variables of HIV-positive women.
Variables HPV infection
Positive (%) Negative (%) RR (IC 95%)
Age (years)
18–24 2.9 3.1 0.71  (0.06–8.54)
25–30 5.9 18.8 0.23 (0.05–0.97)
31–35 17.6 15.6 0.86 (0.25–2.88)
36–39 16.2 18.8 0.65(0.20–2.11)
40–45 57.4 43.8 1
p  = 0.342
Skin color
White 55.9 40.6 2.02 (0.82–4.99)
Non-white 44.1 59.4 1
p  = 0.155
Schooling (years)
>5  23.1 13.3 2.43 (0.66–8.99)
5–8 46.2 43.3 1.50 (0.57–3.89)
>8 30.8 43.3 1
p  = 0.378
Marital status
Married/consensual union 63.2 68.8 1
Single 22.1 18.8 0.99 (0.26–3.78)
Separated/divorced/widowed 14.7 12.5 1.35 (0.27–6.67)
p  = 0.865
Per capita income (minimum wages)
0–1  96.5 96.8 0.91 (0.80–10.53)
2 3.5 3.2 1
p  = 0.944
Family income (minimum wages)
Up  to 1 29.8 32.3  0.18 (0.02–1.72)
Up to 2 33.3  45.2 0.15 (0.01–1.33)
Up to 3 21.1 19.4 0.22 (0.02–2.18)
Over 4 15.8 3.2 1
p  = 0.307
Cigarette smoking
Current  smoker 41.2 38.7 0.90(0.37–2.15)
No-smoker 58.8 61.3 1
p  = 0.817
Alcohol consume (last 4 weeks)
At  least once a week 17.6 25.0 0.75 (0.26–2.12)
Less than once a week 23.5 12.5 2.00 (0.59–6.77)
Never 58.8 62.5 1
p  = 0.375
Use of condom (last sexual activity)
Yes  62.7 65.6 1
No 37.3 34.4 0.88(0.36–2.12)
p  = 0.776
Sexual activity began (years)
<15  51.5 65.6 1.71 (0.47–6.19)
16–18 38.2 15.6 5.19 (1.16–23.17)
≥19 10.3 18.8 1
p  = 0.062
Sexual partners (in life)
Up  to 1 3.0 3.1 1
2–4 39.4 25.0 1.07 (0.90–12.94)
5–8 18.2 28.1 1.75 (0.62–4.87)
≥9 39.4 43.8 0.71 (0.24–2.11)
p  = 0.497
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Table 1 (Continued)
Variables HPV infection
Positive (%) Negative (%) RR (IC 95%)
Give/received drugs and/or money for sex
Yes 80.0 20.0 1.93  (0.20–18.07)
No 67.4 32.6 1
p  = 0.555
Last Pap test
Never  8.6 13.3 0.25 (0.03–1.86)
<3 years 70.7 76.7 1
>3 years 20.7 10.0 0.35 (0.07–1.76)
Do not remember 14.7 6.2 0.80 (0.11–5.77)
p  = 0.336
Visual inspection with acetic acid (VIA)
Positive 10.4 6.7 1.63 (0.31–8.37)
Negative 89.6 93.3 1
p  = 0.553
Visual inspection with Lugol’s iodine (VILI)
Positive 10.4 6.7 1.63 (0.31–8.37)
Negative 89.6 93.3 1
p  = 0.553
Pap test results
Normal 60.7 65.5 1
Inﬂammatory 31.1 27.6 0.77 (0.13–4.39)
Altered 8.2 6.9 0.95 (0.15–5.95)
p  = 0.905
CD4 counting cells (cells/mm3)
<350 25.4 20.0 0.73 (0.25–2.10)
>350 76.3 80.0 1
p  = 0.565
Table 2 – Interaction of Arg72Pro and MDM2  SNP309 on the HPV infection and oncogenic risk status.
HPV infection p HPV genotypes p
HPV-positiven (%) HPV-negativen (%) High-riskan (%) Low-riskan (%)
P53 genotypes
Arg72Arg 31 (45.6) 8 (25) 10 (52.6) 18 (47.4)
Arg72Pro 25 (36.8) 18 (56.2) 0.11 6 (31.6) 14 (36.8) 0.91
Pro72Pro 12 (17.6) 6 (18.8) 3 (15.8) 6 (15.8)
P53 alleles
Arginine carriers 56 (84.2) 26 (81.2) 0.89 16 (84.2) 32 (84.2) 1.00
Proline carriers 37 (554.4) 24 (75) 0.04 9 (47.4) 20 (52.6) 0.70
MDM2 genotypes
TT  23 (33.8) 16 (50) 8 (42.1) 9 (23.7)
TG 34 (50) 11 (34.4) 0.26 6 (31.6) 25 (65.8) 0.04
GG 11 (16.2) 5 (16.2) 5 (26.3) 4 (10.5)
MDM2 alleles
Thymine carriers 57 (83.8) 27 (84.4) 0.94 14 (73.7) 34 (89.5) 0.12






ta Total of 57 samples.
iscussion
tudies have shown that HPV infection is most common in
IV-infected  women  and it is believed that HIV contributes to
ncrease HPV viral load and hence its persistence, increasing
he  risk for cervical intraepithelial lesions.8 The HPV infec-
ion  prevalence in this study was  68%. These observationsare  consistent with a meta-analysis study reported by Clifford
et  al., who observed higher HPV prevalence in HIV-infected
women in Brazil and Mexico (57.3%) compared to the global
prevalence (36.5%).21In this study women older than 40 years, with low income,
early  sexual debut and high number of sexual partners
throughout life showed greater risk to acquire HPV infection.
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Sauvaget et al. in a study conducted with women with average
age  of 39 years from rural areas of India, found an associa-
tion  with low income, early age at ﬁrst pregnancy, and low
educational level.22 They suggested that constant increase
in  HPV prevalence in middle-aged women may  result from
reduced  ability of the host to eliminate HPV infection, nutri-
tional  deﬁciencies, or from the virus ability to become latent
and  be reactivated due to a failure of immune surveillance
or  hormonal factors associated to older age. Moreover, the
HR-HPV  prevalence usually shows a constant decline with
the  increasing age seen in high-income countries, in con-
trast  to the U-shaped curves reported in some Latin-American
countries. Here, an increased prevalence of HPV infection in
the age group of 35–44 years old has been reported in a cross-
sectional  study performed in eleven countries with different
cervical  cancer incidences.23
The genotyping by sequencing showed the presence of
nine  different HPV genotypes, with a higher prevalence for
HPV-6,  followed by HPV-16 and -31 in this study. Although
most  studies show that HPV-16 genotype is the most prevalent
worldwide,21 this data is in line the report by Corrêa et al., who
observed  a prevalence of 63.9% of HPV-6 genotype followed by
HPV-16 genotype as the second most prevalent (48.5%).24 Levi
et  al. observed similar data, with higher prevalence of HPV-
6  genotype in HIV-infected women  (87%).25 McKenzie et al.,
in  a meta-analysis study, observed that different geographic
areas,  such as Zambia, Brazil and Rochester (New York, United
States),  show different HR-HPV infections by less prevalent
genotypes when compared to the population in general.26 Fur-
thermore,  they show that cervical malignancy has a different
behavior  in HIV-infected patients, as well as benign manifes-
tations  of HPV.
Apparently, the HIV infection exerts a multifactorial onco-
genic  function in cervical cancer development, interfering
in  the immune function and also in the direct promotion
of  the lesion development. The HIV-1 Tat protein seems to
promote  the cellular proliferation and positively regulate the
E6  and E7 HPV genes, responsible for the malignant cellu-
lar  transformation.27,28 Recent data indicate that signiﬁcant
changes occur in the uterine cervix in HPV/HIV co-infected
women  suggesting that the immune response appears to be
negatively regulated, except for the RANTES protein (Regu-
lated  on Activation, Normal T cell Expressed and Secreted),
which  has been found to be increased.29 RANTES levels
were  found signiﬁcantly increased in plasma and tissue from
patients  with breast cancer and cervical cancer, suggesting
that  positive regulation of RANTES and other changes in cer-
vical  tissue associated with HPV/HIV co-infection (such as
those  mediated by HIV-1 Tat protein) would permit less aggres-
sive  HPV genotypes to cause malignant transformation.30
Some authors suggest that this variation of genotypes is due
to  socioeconomic and behavioral characteristics, which may
be  different in HIV-infected women, besides the geographic
region  where the research is conducted.31 With regard to
HPV  infection stratiﬁed by genotype, further studies com-
paring  innate immunity between HIV+ and HIV− women
are  necessary. These studies will help to individualize treat-
ment  and prevention in the group of women at increased
risk  of morbidity and mortality due to HPV-related dis-
eases. 1 4;1  8(6):643–650
The  ability of the persistent HPV infection to cause malig-
nant  transformation is associated to the viral DNA integration
into  the genome of the host.32 However, some studies have
challenged this statement. These studies indicate that the
necessity  of integration for the carcinogenesis varies with the
HPV  genotype (for example, only 50% of the HPV-16 genome
integrates with the host, while HPV-18 needs to integrate
94%).33 This distinction is particularly important for the com-
prehension of the disease etiology in HIV-infected patients,
since  these are commonly infected by HPV genotypes that
require  integration with the host genome for the carcinogene-
sis  development. Furthermore, recent studies have described
the  association between the integration rate and the cervical
dysplasia  severity.34
Concerning the Arg72Pro TP53 gene polymorphism, the
present  study found no statistically signiﬁcant relation
between observed genotypes, frequency of the Arg and Pro
alleles  and HPV presence. Moreover, it is worth noting that the
controversial  results regarding the association between TP53
gene  polymorphism and cervical cancer can occur due to some
factors,  such as differences in the TP53 polymorphism among
ethnical  groups, sample size, choice of the control to be used
and  DNA obtaining source.35 For an example, a study using
normal  cervical samples and high- and low-risk lesion sam-
ples  failed to show an association between the presence of
the  polymorphism and frequency of the Arg and Pro alleles
with  increased risk for CC,12 suggesting that the association
between the TP53 gene polymorphism and the development of
HPV-associated  cervical neoplasia is improbable. However, in a
meta-analysis study performed one year later, it was  observed
signiﬁcantly higher odds of progression from SIL to CC with
the  p53 Arg allele [OR 1.37; 95% CI, 1.15–1.62; p < 0.001] in HPV-
positive  individuals.36
There are a few studies correlating MDM2 SNP309 to CC
susceptibility, although SNP309 presents a relatively high fre-
quency in the general population and its presence has been
associated  with the acceleration of tumorigenesis and time
of  tumor onset.10 In this study, TT and TG genotypes were
signiﬁcantly more  frequent in HR-HPV and LR-HPV groups,
respectively, but presence or frequency of the T and G alleles
was  not signiﬁcantly associated with HPV infection. There is
an inconsistency regarding the role of MDM2 SNP309 in sus-
ceptibility  to the CC development. Nunobiki et al. found a
prevalence  of 78.8% for the TG genotype among high-grade
squamous intraepithelial lesion (HSIL) samples when com-
pared  with low-grade squamous intraepithelial lesion (LSIL)
samples  and controls, among HR-HPV positive samples and,
specially,  the HPV-16 and -18 genotypes.11 However, there was
no  association between the samples and the frequencies of T
and G alleles. Meissner et al. in a study conducted in North-
eastern  Brazil for identiﬁcation of the MDM2  SNP309 in 72 CC
samples  and 100 normal samples by PCR found no statisti-
cally  signiﬁcant association between the SNP309 and the risk
and  early diagnosis for CC.37 Also, no difference was  observed
for  the frequency of alleles or genotypes among the group of
patients  diagnosed with CC at an early age (below 40 years)
and  the group of older patients. On the other hand, Arvan-
tis  and Spandidos through the analysis of mRNA  expression
proﬁles of 24 G1- and S-phase checkpoint genes in 35 cervical
carcinomas samples, 26 HSIL samples, 33 LSIL samples, and
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8 normal cervical samples (used as controls), showed that
he  MDM2  was  found positively regulated in SIL, suggesting
hat  MDM2  gene is a potential candidate for cervical neopla-
ia  development.38 Although this data suggest that HR-HPV
nfection and the MDM2  SNP309 may  be associated with cer-
ical  carcinogenesis, in our study there were no samples from
atients  with CC, which can be considered a limiting factor
or  these two associations types, since the polymorphisms of
oth  MDM2  and TP53 genes are associated with increased risk
or  CC and not with susceptibility to HPV infection.
A better understanding of the HPV infection evolution in
hese  women, the viral persistence occurrence, and possible
actors  associated to the malignant cervical lesions devel-
pment  are necessary for establishing more  appropriate CC
creening  routines in this population. This is essential for
he  proposition of more  appropriate monitoring strategies and
reatment  according to the Brazilian health service reality, as
ell as patients.
onclusion
urrent recommendations are partly based on the knowl-
dge  of professionals about CC management and HIV infection
n  women. The data obtained in this study suggest that
IV-infected women  are more  susceptible to be infected by
he  LR-HPV genotypes than by the high-risk HR-HPV. Addi-
ionally,  Pro72Pro of TP53 gene and TG of MDM2  SNP309
enotypes apparently seem to be protective factors among
I-infected women  for HPV acquisition and HR-HPV infec-
ion,  respectively, in a sample of Southern Brazilian woman.
oreover, further studies are necessary for the investigation
f  the behavior of low-risk genotypes infecting HIV-mediated
mmunosuppressed cases.
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